Last 2 paragraphs of the conclusion sound rather positive!!...the down rampers are on early it seems.
"....Remestemcel-L was well tolerated with a favorable safety profile compared to currently available therapies. The most frequently reported AEs in Study GVHD001 were those commonly seen in the pediatric SR-aGVHD population, such as infections, GI disorders, and respiratory complications. The demonstrated efficacy and favorable safety profile of remestemcel-L address a significant unmet medical need in pediatric SR-aGVHD patients, especially in children under the age of 12 years old.
Considered in the context of a serious condition for which currently available treatments have limitations, the totality of evidence substantiates the highly favorable clinical benefit-risk profile for remestemcel-L in the treatment of pediatric patients with SR-aGVHD."
Last 2 paragraphs of the conclusion sound rather...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.030(2.60%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $8.949M | 7.569M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 135615 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 207924 | 17 |
View Market Depth
| Last trade - 12.29pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.030 ( 3.84 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 1482449 | ||
| Last updated 12.47pm 07/05/2024 ? | |||||
| MSB (ASX) Chart |